Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral adrenoleukodystrophy
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral adrenoleukodystrophy US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) Mataró, Barcelona,...
Source: pharmiweb.com